Receiving a Pathogenic Variant in a Population Breast Cancer Screening Trial: A Mixed Method Study
Although most participants communicated results with family members and healthcare providers in accordance with their risk level, questions remain about how to adequately prepare individuals to receive pathogenic results, ensure timely and accessible follow-up care, and facilitate genetic counseling and cascade testing of at-risk relatives in the setting of population risk-based screening.
Authors
- Leah Sabacan
- Leslie Riddle (ORCID: https://orcid.org/0000-0002-1577-2762)
- Diane Heditsian
- Galen Joseph (ORCID: https://orcid.org/0000-0001-9179-7075)
- Jennifer E. James (ORCID: https://orcid.org/0000-0001-6240-3487)
- Barry Tong (ORCID: https://orcid.org/0000-0003-3433-7296)
- Katherine Ross
- Barbara A. Koenig (ORCID: https://orcid.org/0000-0003-3227-6768)
- Arash Naeim (ORCID: https://orcid.org/0000-0001-6830-5933)
- Martin Eklund (ORCID: https://orcid.org/0000-0001-5032-5266)
- Neil S. Wenger (ORCID: https://orcid.org/0000-0002-9884-3967)
- Diana De Rosa
- Lisa Madlensky
- Allison Stover Fiscalini (ORCID: https://orcid.org/0000-0002-9639-4053)
- Susie Brain
Institutions
- Cancer Prevention Institute of California (US)
- University of California, Los Angeles (US)
- University of California, San Francisco (US)
- UCLA Health (US)
- Karolinska Institutet (SE)
- Institute on Aging (US)
- Cancer Genetics (United States) (US)
Publication Details
- Journal
- Public Health Genomics
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1159/000540680
- Citations
- 2
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.10
Funders
- National Cancer Institute